,,ii  #aahth ,,congress  #b;d ,session  
,s4 #dgda  ,,in ,,the ,,senate ,,of     
,,the ,,united ,,states  ,july #bc1     
#bjbd,mr4 ,tillis 7for himself and ,mr4 
,kelly7 introduced the following bill2  
which was read twice and referred to the
 ,committee on ,finance  ,a ,,bill  ,to 
amend title ,,xviii of the ,social      
,security ,act to provide a phase-in for
 plasma-derived products under the      
manufacturer discount program4  #a4     
,short title ,this ,act may be cited as 
the ,preserving ,life-saving ,access to 
,specialty ,medicines in ,america ,act  
or the ,,plasma ,act4  #b4 ,phase-in for
 plasma-derived products under          
manufacturer discount program ,section  
#ahfj;,d-#ad;,c7g77#d7 of the ,social   
,security ,act 7#db ,u4,s4,c4           
#aciew-#aad;c7g77#d77 is amended-- 7#a7 
in subparagraph 7,a71 in the matter     
preceding clause 7i71 by striking and   
7,c7 and inserting 1 7,c71 and 7,d72    
7#b7 by redesignating subparagraphs 7,d7
 and 7,e7 as subparagraphs 7,e7 and     

7,f71 respectively2 and  7#c7 by        
inserting after subparagraph 7,c7 the   
following3  7,d7 ,phase-in for          
plasma-derived products  7i7 ,in general
 ,in the case of an applicable drug that
 is a plasma-derived product 7as defined
 in clause 7ii771 and that is marketed  
as of the date of enactment of this     
subparagraph and dispensed for an       
applicable beneficiary1 the term        
discounted price means the specified    
plasma-derived product percent 7as      
defined in clause 7iii77 of the         
negotiated price of the applicable drug 
of the manufacturer4  7ii7              
,plasma-derived product ,in this        
subparagraph1 the term plasma-derived   
product means an applicable drug that is
 a biological product that is derived   
from human whole blood or plasma4  7iii7
 ,specified plasma-derived product      
percent ,in this subparagraph1 the term 
specified plasma-derived product percent
 means1 with respect to a year-- 7,i7   
for an applicable drug that is as a     

plasma-derived product dispensed for an 
applicable beneficiary who has not      
incurred costs1 as determined in        
accordance with section                 
#ahfj;,d-#b7;b77#d77;,c71 for covered   
part ,d drugs in the year that are equal
 to or exceed the annual out-of-pocket  
threshold specified in section          
#ahfj;,d-#b7;b77#d77;,b77i7 for the     
year1 the percent specified under       
subparagraph 7,b77iii77,i7 for such     
year2 and  7,,ii7 for an applicable drug
 that is as a plasma-derived product    
dispensed for an applicable beneficiary 
who has incurred costs1 as determined in
 accordance with section                
#ahfj;,d-#b7;b77#d77;,c71 for covered   
part ,d drugs in the year that are equal
 to or exceed the annual out-of-pocket  
threshold specified in section          
#ahfj;,d-#b7;b77#d77;,b77i7 for the     
year1 the percent specified under       
subparagraph 7,b77iii77,,ii7 for such   
year4  4